The Pharmacy Times® Neurology Resource Center is a comprehensive resource for clinical news and expert insights on disorders of the nervous system, including multiple sclerosis, Alzheimer disease, migraine, and Parkinson disease.
May 9th 2024
The results also showed that the PET scans could show damage to the individual’s brains, which was correlated with disability and fatigue.
Understanding the Role of IVIg and SCIg for the Management of CIDP: Information the Pharmacist Needs to Know to Optimize Care, featuring a Patient Perspective
1.5 Credits / Immunology, Neurology
View More
Rare and Treatment-Resistant Epilepsy Syndromes: Identifying and Addressing the Unmet Needs of Patients and Recognizing Opportunities for Pharmacist Intervention
1.5 Credits / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Navigating the Use of Targeted Therapies and Individualizing Care for Patients With Ulcerative Colitis
1.5 Credits / Gastroenterology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Advances in Pharmacotherapy for Excessive Daytime Sleepiness Due to Narcolepsy
2.0 Credits / Neurology
View More
The Role of Long-Term Care and Consultant Pharmacists in the Management of Tardive Dyskinesia
1.0 Credit / Neurology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Specialty Pharmacy Considerations for Oral Multiple Sclerosis Therapies
October 9th 2013Multiple sclerosis treatment options have expanded dramatically over the past several years. In addition to subcutaneous and intravenous medications, there are now 3 disease-modifying oral therapies available in the United States.
Read More
Hospital Admissions and MS: Temporal Trends and Patient Characteristics
January 10th 2013Patients with a longer disease duration and those with primary progressive MS were found to have higher rates of admission and longer hospital stays in this study from The American Journal of Managed Care.
Read More
EMD Serono and Pfizer Announce FDA Approval of Rebif Rebidose (interferon beta-1a)
January 4th 2013EMD Serono, Inc, a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc announced today that the FDA approved Rebif Rebidose (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS).
Read More
Higher Copays for Multiple Sclerosis Medications Contribute to Poor Patient Compliance, Outcomes
November 22nd 2012A recent study featured in the American Journal of Pharmacy Benefits examines the role of patient out-of-pocket cost on adherence to disease-modifying therapies for multiple sclerosis.
Read More
The Specialty Pharmacy Pipeline: What's Next?
October 17th 2012In a session at the 2012 Academy of Managed Care Pharmacy Educational Conference, Aimee Tharaldson, PharmD, identified the top specialty drugs in the pipeline and highlighted the most recent therapeutic trends within each medication class.
Read More
Multiple Sclerosis Drug Costs Account for More Than Two-Thirds of Patients' Total Cost of Care
October 17th 2012A new study carried out by Blue Cross and Blue Shield of Minnesota and PBM Prime Therapeutics forecasts that multiple sclerosis specialty drug treatment cost will exceed $50,000 per person per year in 2016.
Read More